Does Rallies show live market data for ABUS?

Rallies combines live market context with ticker research for ABUS, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

ABUS (Arbutus Biopharma Corporation Common Stock) Stock Analysis

Arbutus Biopharma Corporation Common Stock (ABUS) is a publicly traded Healthcare sector company. As of May 20, 2026, ABUS trades at $4.43 with a market cap of $823.73M and a P/E ratio of 5.20. ABUS moved +3.81% today. Year to date, ABUS is -7.22%; over the trailing twelve months it is +36.14%. Its 52-week range spans $2.71 to $5.10. Rallies surfaces ABUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest ABUS stock research?

Arbutus Biopharma Corporation Common Stock (ABUS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ABUS moved +3.81% today.

ABUS Key Metrics

Key financial metrics for ABUS
Metric	Value
Price	$4.43
Market Cap	$823.73M
P/E Ratio	5.20
EPS	$0.84
Dividend Yield	0.00%
52-Week High	$5.10
52-Week Low	$2.71
Volume	2.19M
Avg Volume	0
Revenue (TTM)	$191.44M
Net Income	$160.72M
Gross Margin	0.00%

Latest ABUS News

Moderna Q1 Revenue Triples to $389M with $311M International COVID Sales — May 1, 2026
Arbutus Biopharma Secures FDA Fast Track for Imdusiran After 10 HBV Functional Cures — Apr 15, 2026
Arbutus Secures $2.25B Moderna Settlement and Reports $91.5M Cash Position — Mar 23, 2026
Arbutus to Receive $950M Upfront, Up to $2.25B From Moderna Settlement — Mar 4, 2026
Arbutus Biopharma to Receive Share of $950M Moderna Settlement, Eyeing $1.3B Appeal Upside — Mar 4, 2026

Recent ABUS Insider Trades

HASTINGS DAVID C sold 22.18K (~$72.83K) on Feb 4, 2025.
Sims Karen sold 19.35K (~$63.52K) on Feb 4, 2025.
McElhaugh Michael J. sold 23.79K (~$78.10K) on Feb 4, 2025.

ABUS Analyst Consensus

ABUS analyst coverage data. Average price target: $0.00.

Common questions about ABUS

What can I research for ABUS on Rallies?: Arbutus Biopharma Corporation Common Stock (ABUS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ABUS moved +3.81% today.
Does Rallies show live market data for ABUS?: Rallies combines live market context with ticker research for ABUS, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.